KPTI Stock Price History and Quote Analysis: Insights for Investors

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own KPTI shares is 138, representing 56.69% of the company's common stock.

AMERICAN INTERNATIONAL GROUP, INC., in the last quarter, reduced its stake in KPTI by -0.85% restricting it's holding to 55.82 thousand shares of worth nearly $84.28K. INVESCO LTD. also lessened -1.76% of the KPTI shares from its portfolio, reducing its holding to 27.97 thousand shares of worth $42.23K. STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM also shunned KPTI shares holding by -8.18% last quarter which brought its holding to 27.02 thousand shares worth $105.09K.

As per its latest 13F filing, CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. increased its stake in KPTI by 7.15% in the last quarter. The institutional holder raised its holding to 76.32 thousand shares having worth more than $115.24K. METLIFE INVESTMENT MANAGEMENT, LLC also added 100% more shares of KPTI to its portfolio, raising its holding to 60.55 thousand shares of worth $91.43K. SIMPLEX TRADING, LLC also increased its KPTI shares holding by 166.58% which brought its holding to 55.99 thousand shares worth $84.00K.

The insider with the most stakes in KPTI is Paulson Richard A. , President and CEO at the company. Additionally, KPTI stock is highly held by Chief Scientific Officer Shacham Sharon and director Kauffman Michael among others.

Company executives, directors, and other insiders own 6.07% percent of Karyopharm Therapeutics Inc.'s stock. Within the last six months, there have been 18 transaction(s) in which KPTI insiders have sold stock, totaling 65.04K shares. Insiders that have sold shares include PAULSON RICHARD A., MASON MICHAEL, and CHENG SOHANYA ROSHAN.

There have been 0 transaction(s) during the past 6-months in which Karyopharm Therapeutics Inc. insiders have bought stock, totalling 0 shares

Around 9.04M Karyopharm Therapeutics Inc. shares are held by insiders, which represents about 6.07% of KPTI stock.

KPTI President and CEO, Paulson Richard A. holds the largest portfolio of the company's shares. KPTI shares owned by Paulson total nearly 1.14 million.

CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. is the largest institutional owner in KPTI which holds 76.32 thousand shares worth $115.24K or 0.07% of the total KPTI shares outstanding followed by METLIFE INVESTMENT MANAGEMENT, LLC with ownership of 60.55 thousand shares representing 0.05% of the KPTI ownership. SIMPLEX TRADING, LLC is the third largest stakeholder with 55.99 thousand shares or 0.05% of the ownership worth more than $84.00K.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the KPTI is concerned, it is a stock which is optionable.

Number of KPTI shares short is 18.60M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 124.68M shares of KPTI are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, KPTI has 123.03M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for KPTI is 28.47.